Egress of CD19 + CD5 + cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.

Slides:

Advertisements

Similar presentations

Wilson WH et al. Proc ASH 2012;Abstract 686.

Advertisements

Lymphoma dissemination: the other face of lymphocyte homing by Steven T. Pals, David J. J. de Gorter, and Marcel Spaargaren Blood Volume 110(9):

CLL Stromal cell protect Conventional therapies Versteckspiel im Wald by Friedrich Eduard Meyerheim ( ) The “outside” (microenvironment) of the.

Interim Results of an International, Multicenter, Phase 2 Study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory.

Ibrutinib (PCI-32765) First-In-Class BTK Inhibitor IM Los Angeles 18 Jan

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications by Elias Campo, Steven H. Swerdlow, Nancy L.

SAP mediates specific cytotoxic T-cell functions in X- linked lymphoproliferative disease by Reza Sharifi, Joanna C. Sinclair, Kimberly C. Gilmour, Peter.

Evidence for anti-inflammatory activity of statins and PPARα activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes.

Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma by Salvia Jain, Dina Stroopinsky, Li Yin, Jacalyn Rosenblatt, Maroof Alam, Parul.

Inhibition of NF-κB induces apoptosis of KSHV-infected primary effusion lymphoma cells by Shannon A. Keller, Elaine J. Schattner, and Ethel Cesarman Blood.

Lenalidomide augments actin remodeling and lowers NK- cell activation thresholds by Kathryn Lagrue, Alex Carisey, David J. Morgan, Rajesh Chopra, and Daniel.

Constitutive NF-κB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B- cell lymphomas by Lingchen Fu, Yen-Chiu Lin-Lee,

Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells by Jonathan M. Irish,

Determination of acute lung injury after repeated platelet transfusions by Laurence Corash, Jin Sying Lin, Claire D. Sherman, and Joseph Eiden Blood Volume.

PI 3-kinase inhibition has no effect on ANG II induced extracellular recognition kinase (ERK) 1/2 activation. PI 3-kinase inhibition has no effect on ANG.

IMBRUVICA® (ibrutinib)

VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome.

The PI3K Delta Inhibitor TGR-1202 and Proteasome Inhibitor Carfilzomib Are Highly Synergistic In Killing Human B- and T-Cell Lymphoma Cells by Changchun.

TCR-MHC-peptide(s): in vivo veritas

Fledgling prognostic markers in CLL

Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy by Georg.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response by Andreas Rosenwald, Eric Y. Chuang,

BRAF inhibitor: targeted therapy in hairy cell leukemia

How I treat elderly patients with myeloma

Skovseth et al. Endostatin dramatically inhibits endothelial cell migration, vascular morphogenesis, and perivascular cell recruitment in vivo. Blood.

The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naïve.

SOX11 holds mantle cell lymphoma’s key to home

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized.

Lymphoma dissemination: the other face of lymphocyte homing

Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome by Kerry J.

Small-molecule inhibitor QLT-0267 suppresses ILK activity and inhibits its downstream signaling. Small-molecule inhibitor QLT-0267 suppresses ILK activity.

Targeting kinases in CML CLL

Relationship of p53, bcl-2, and Tumor Proliferation to Clinical Drug Resistance in Non-Hodgkin's Lymphomas by Wyndham H. Wilson, Julie Teruya-Feldstein,

Cytokine and chemokine expression of flucloxacillin-specific T cell clones (TCC) of patient P1. Cytokine and chemokine expression of flucloxacillin-specific.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

by Paolo Strati, Michael J. Keating, William G. Wierda, Xavier C

Ph+ ALL: drawing strength from a benign past

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma by Hannes Kaufmann, Markus Raderer, Stefan Wöhrer,

Lymphoma spread? Target CD47-SIRPα!

HU for acute treatment of sickle VOC?

Vascular endothelial growth factor stimulates protein kinase CβII expression in chronic lymphocytic leukemia cells by Simon T. Abrams, Benjamin R. B. Brown,

Induction of antigen-specific regulatory T lymphocytes by human dendritic cells expressing the glucocorticoid-induced leucine zipper by Haifa Hamdi, Véronique.

Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray by Wolf-K. Hofmann, Sven de Vos, Kunihiro Tsukasaki, William.

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma by Young Ae Kim, Ja Min Byun, Keeho Park, Gi Hwan Bae, Dukhyoung.

Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma by Hanna Karvonen, David Chiron, Wilhelmiina Niininen,

by Kamira Maharaj, John J

TNF-α–stimulated adhesion of HL60 cells to HCMEC is inhibited by neuraminidase but not by NaClO3 . TNF-α–stimulated adhesion of HL60 cells to HCMEC is.

Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma by Jimmy Lee, Liang Leo Zhang, Wenjun.

Arp2/3-mediated formation of nuclear actin networks is essential for CD4+ T cell effector functions. Arp2/3-mediated formation of nuclear actin networks.

Interleukin-2–inducible T-cell kinase inhibitors modify functional polarization of human peripheral T-cell lymphoma cells by Sami Mamand, Matthew Carr,

Hematopoietic potential of HEP from patient-specific iPSC may be reduced. Hematopoietic potential of HEP from patient-specific iPSC may be reduced. (A)

Src kinases mediate TSP-1 inhibition of AC and PKA activity.

Schematic model of the mechanism of Tak1 protection of HSPC survival.

Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study by Jeffrey.

Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients by Marcel W. Bekkenk, Maarten.

Influence of the tumor microenvironment on FL

Relationship of PMBL to Hodgkin lymphoma.

CR-rate ratios with 95% CIs

The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells.

Hepatosplenic T-Cell Lymphoma: Clinicopathological Features and Treatment Outcomes: Report From The North American Peripheral T-Cell Lymphoma Consortium.

by Holbrook E Kohrt, Idit Sagiv-Barfi, Sarwish Rafiq, Sarah E. M

by Dana S. Levy, Jason A. Kahana, and Rakesh Kumar

Patient Tregs express normal levels of suppression.

Signals and transcription factors involved in B-cell PD-1 induction.

by Wolfgang Warsch, Christoph Walz, and Veronika Sexl

ARQ 531 is cytotoxic to CLL cells, decreases NF-κB function, and inhibits migration. ARQ 531 is cytotoxic to CLL cells, decreases NF-κB function, and inhibits.

Inhibition of BCR-mediated signaling by ARQ 531.

Presentation transcript:

Egress of CD19 + CD5 + cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients by Betty Y. Chang, Michelle Francesco, Martin F. M. De Rooij, Padmaja Magadala, Susanne M. Steggerda, Min Mei Huang, Annemieke Kuil, Sarah E. M. Herman, Stella Chang, Steven T. Pals, Wyndham Wilson, Adrian Wiestner, Marcel Spaargaren, Joseph J. Buggy, and Laurence Elias Blood Volume 122(14): October 3, 2013 ©2013 by American Society of Hematology

Transient mobilization of lymphocytes in MCL patients treated with ibrutinib. Chang B Y et al. Blood 2013;122: ©2013 by American Society of Hematology

CD19+CD5+ cells have decreased CXCR4, CD38, and Ki67 expression following ibrutinib treatment. Chang B Y et al. Blood 2013;122: ©2013 by American Society of Hematology

Ibrutinib inhibits migration of MCL cells beneath stromal cells (pseudo-emperipoiesis) and the formation of CXCL12-stimulated cortical actin. Chang B Y et al. Blood 2013;122: ©2013 by American Society of Hematology

Ibrutinib suppresses BCR- and coculture-stimulated signaling and cytokine and chemokine production of MCL cells. Chang B Y et al. Blood 2013;122: ©2013 by American Society of Hematology

Ibrutinib inhibits BCR-activated adhesion of MCL cells. Chang B Y et al. Blood 2013;122: ©2013 by American Society of Hematology

Ibrutinib inhibits CXCL12-/CXCL13-activated adhesion and migration of MCL cells. Chang B Y et al. Blood 2013;122: ©2013 by American Society of Hematology

Ibrutinib inhibits BCR- and chemokine-induced adhesion of primary MCL cells. Chang B Y et al. Blood 2013;122: ©2013 by American Society of Hematology